Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ifosfamide Clear all
Terminated Phase 2 Interventional

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

NCT00003292
View directory record Official record
Conditions
Chondrosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Rhabdomyosarcoma, Adult Malignant Meningioma, Adult Brain Malignant Hemangiopericytoma
Interventions
ifosfamide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
65
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

NCT02432274
View directory record Official record
Conditions
Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
Interventions
Lenvatinib, Ifosfamide, Etoposide
Drug
Lead sponsor
Eisai Limited
Industry
Eligibility
2 Years to 25 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

NCT00002565
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, CHOP regimen, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, idarubicin, ifosfamide, mesna, methylprednisolone, mitoxantrone hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

NCT00002816
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

NCT02235701
View directory record Official record
Conditions
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Interventions
170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
15 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 2, 2026, 2:13 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of N9 Chemotherapy in Children With Neuroblastoma

NCT04947501
View directory record Official record
Conditions
Neuroblastoma, Pediatric Cancer
Interventions
Cyclophosphamide, Topotecan, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Carboplatin, Mesna
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 19 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

NCT00003776
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, ifosfamide, leucovorin calcium, methotrexate, trimetrexate glucuronate, surgical procedure
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

NCT00358540
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Santa Monica, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

NCT03440567
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin, Etoposide Phosphate, Ibrutinib, Ifosfamide, Laboratory Biomarker Analysis, Rituximab, Utomilumab
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 2:13 AM EDT
Terminated Phase 3 Interventional Results available

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

NCT02137096
View directory record Official record
Conditions
Recurrent Nasopharynx Carcinoma
Interventions
Etoposide phosphate, Carboplatin, Ifosfamide, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

NCT00439361
View directory record Official record
Conditions
Hodgkin Lymphoma, Lymphoma
Interventions
Bortezomib, Carboplatin, Etoposide, Ifosfamide, Mesna
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2012 · Synced Sep 2, 2026, 2:13 AM EDT
Terminated Phase 2 Interventional Results available

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00809341
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Ifosfamide, Carboplatin, Etoposide, High-dose cyclophosphamide, PET scan
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 2, 2026, 2:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

NCT03016871
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Carboplatin, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Nivolumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Duarte, California • New Haven, Connecticut • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 2:13 AM EDT
Not listed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

NCT00012311
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 59 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 2, 2026, 2:13 AM EDT
Withdrawn Not applicable Interventional

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

NCT01795430
View directory record Official record
Conditions
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
etoposide, ifosfamide, intensity-modulated radiation therapy, topotecan hydrochloride, busulfan, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, autologous bone marrow transplantation
Drug · Radiation · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Caphosol in Sarcoma Patients With Mucositis

NCT00965172
View directory record Official record
Conditions
Sarcoma, Oral Mucositis
Interventions
Caphosol, Baking Soda
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

NCT01097057
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Carboplatin, Etoposide, Filgrastim, Ifosfamide, Leukapheresis, Plerixafor, Rituximab
Drug · Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 2, 2026, 2:13 AM EDT
Terminated Not applicable Interventional Results available

Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia

NCT01230788
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia, ALL
Interventions
rituximab
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Atlanta, Georgia • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 30, 2014 · Synced Sep 2, 2026, 2:13 AM EDT
Terminated Phase 2 Interventional Results available

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01808534
View directory record Official record
Conditions
Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
Interventions
palifosfamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

NCT00039195
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 64 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma

NCT00003575
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, recombinant interleukin-12, etoposide, ifosfamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

NCT00002524
View directory record Official record
Conditions
Lymphoma
Interventions
Bleomycin Sulfate, Filgrastim, Cisplatin, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride (DOX), Etoposide, Fluorouracil, Ifosfamide, Leucovorin calcium, Methotrexate, Methylprednisolone, Pentamidine, Prednisone, Trimethoprim-Sulfamethoxazole, Vincristine Sulfate, Zidovudine (AZT), Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2005
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Not applicable Interventional Results available

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

NCT00618813
View directory record Official record
Conditions
Ewing Sarcoma of Bone, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions
radiation therapy, therapeutic conventional surgery, etoposide, ifosfamide, doxorubicin hydrochloride, cyclophosphamide, vincristine sulfate, topotecan hydrochloride, filgrastim
Other · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 2, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

NCT00467051
View directory record Official record
Conditions
Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor, Testicular Yolk Sac Tumor
Interventions
Carboplatin, Filgrastim, Ifosfamide, Laboratory Biomarker Analysis, Paclitaxel
Drug · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
85
States / cities
Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 2, 2026, 2:13 AM EDT